Developed in the early 1960s, time-domain electromagnetics, the study of electromagnetic-wave propagation from a time-domain perspective, has given birth to a fascinating new technology, which today ...is commonly referred to as ultra-wideband (UWB). It has now been slightly more than 25 years since the 1978 seminal paper of Bennett and Ross, which summarized UWB's early applications. It thus seems appropriate, given the tremendous increase in interest in the technology since the Federal Communications Commission modified its Part 15 rules to accommodate UWB transmissions, to take a look at more recent system applications of this unique technology. This paper provides a brief historical perspective of UWB, discusses recent techniques for the generation and reception of short-pulse electromagnetic waveforms, and examines a number of recently developed UWB systems in the communications, radar, and precision-positioning fields. Finally, a brief assessment of future trends for the technology is provided.
Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and predicting its outcome. We sought to characterize the natural variabilty and performance characteristics of ...14 promising DILI biomarker candidates. Serum or plasma from multiple cohorts of healthy volunteers (n = 192 and n = 81), subjects who safely took potentially hepatotoxic drugs without adverse effects (n = 55 and n = 92) and DILI patients (n = 98, n = 28, and n = 143) were assayed for microRNA‐122 (miR‐122), glutamate dehydrogenase (GLDH), total cytokeratin 18 (K18), caspase cleaved K18, glutathione S‐transferase α, alpha‐fetoprotein, arginase‐1, osteopontin (OPN), sorbitol dehydrogenase, fatty acid binding protein, cadherin‐5, macrophage colony‐stimulating factor receptor (MCSFR), paraoxonase 1 (normalized to prothrombin protein), and leukocyte cell‐derived chemotaxin‐2. Most candidate biomarkers were significantly altered in DILI cases compared with healthy volunteers. GLDH correlated more closely with gold standard alanine aminotransferase than miR‐122, and there was a surprisingly wide inter‐ and intra‐individual variability of miR‐122 levels among healthy volunteers. Serum K18, OPN, and MCSFR levels were most strongly associated with liver‐related death or transplantation within 6 months of DILI onset. Prediction of prognosis among DILI patients using the Model for End‐Stage Liver Disease was improved by incorporation of K18 and MCSFR levels. Conclusion: GLDH appears to be more useful than miR‐122 in identifying DILI patients, and K18, OPN, and MCSFR are promising candidates for prediction of prognosis during an acute DILI event. Serial assessment of these biomarkers in large prospective studies will help further delineate their role in DILI diagnosis and management.
Acute liver failure (ALF) is classically defined by coagulopathy and hepatic encephalopathy (HE); however, acute liver injury (ALI), i.e., severe acute hepatocyte necrosis without HE, has not been ...carefully defined nor studied. Our aim is to describe the clinical course of specifically defined ALI, including the risk and clinical predictors of poor outcomes, namely progression to ALF, the need for liver transplantation (LT) and death.
386 subjects prospectively enrolled in the Acute Liver Failure Study Group registry between 1 September 2008 through 25 October 2013, met criteria for ALI: International Normalized Ratio (INR)≥2.0 and alanine aminotransferase (ALT)≥10 × elevated (irrespective of bilirubin level) for acetaminophen (N-acetyl-p-aminophenol, APAP) ALI, or INR≥2.0, ALT≥10x elevated, and bilirubin≥3.0 mg/dl for non-APAP ALI, both groups without any discernible HE. Subjects who progressed to poor outcomes (ALF, death, LT) were compared, by univariate analysis, with those who recovered. A model to predict poor outcome was developed using the random forest (RF) procedure.
Progression to a poor outcome occurred in 90/386 (23%), primarily in non-APAP (71/179, 40%) vs. only 14/194 (7.2%) in APAP patients comprising 52% of all cases (13 cases did not have an etiology assigned; 5 of whom had a poor outcome). Of 82 variables entered into the RF procedure: etiology, bilirubin, INR, APAP level and duration of jaundice were the most predictive of progression to ALF, LT, or death.
A majority of ALI cases are due to APAP, 93% of whom will improve rapidly and fully recover, while non-APAP patients have a far greater risk of poor outcome and should be targeted for early referral to a liver transplant center.
ABSTRACT
We present a study designed to measure the average Lyman-continuum escape fraction (〈fesc〉) of star-forming galaxies at z ≃ 3.5. We assemble a sample of 148 galaxies from the VANDELS ...spectroscopic survey at 3.35 ≤ zspec ≤ 3.95, selected to minimize line-of-sight contamination of their photometry. For this sample, we use ultra-deep, ground-based, U-band imaging and Hubble Space Telescope V-band imaging to robustly measure the distribution of $\mathcal {R_{\rm obs}}\, =(L_{\rm LyC}/L_{\rm UV})_{\rm obs}$. We then model the $\mathcal {R_{\rm obs}}$ distribution as a function of 〈fesc〉, carefully accounting for attenuation by dust, the intergalactic medium and the circumgalactic medium. A maximum likelihood fit to the $\mathcal {R_{\rm obs}}$ distribution returns a best-fitting value of $\langle f_{\rm esc}\rangle =0.07^{+0.02}_{-0.02}$, a result confirmed using an alternative Bayesian inference technique (both techniques exclude 〈fesc〉 = 0.0 at >3σ). By splitting our sample in two, we find evidence that 〈fesc〉 is positively correlated with Ly α equivalent width (Wλ(Ly α)), with high and low Wλ(Lyα) subsamples returning values of $\langle f_{\rm esc}\rangle =0.12^{+0.06}_{-0.04}$ and $\langle f_{\rm esc} \rangle =0.02^{+0.02}_{-0.01}$, respectively. In contrast, we find evidence that 〈fesc〉 is anticorrelated with intrinsic UV luminosity and UV dust attenuation; with low UV luminosity and dust attenuation subsamples both returning best fits in the range 0.10 ≤ 〈fesc〉 ≤ 0.22. We do not find a clear correlation between fesc and galaxy stellar mass, suggesting stellar mass is not a primary indicator of fesc. Although larger samples are needed to further explore these trends, our results suggest that it is entirely plausible that the low dust, low-metallicity galaxies found at z ≥ 6 will display the 〈fesc〉 ≥ 0.1 required to drive reionization.
This paper addresses the challenge of producing multifunctional composites that can simultaneously carry mechanical loads whilst storing (and delivering) electrical energy. The embodiment is a ...structural supercapacitor built around laminated structural carbon fibre (CF) fabrics. Each cell consists of two modified structural CF fabric electrodes, separated by a structural glass fibre fabric or polymer membrane, infused with a multifunctional polymeric electrolyte. Rather than using conventional activated carbon fibres, structural carbon fibres were treated to produce a mechanically robust, high surface area material, using a variety of methods, including direct etching, carbon nanotube sizing, and carbon nanotube
in situ
growth. One of the most promising approaches is to integrate a porous bicontinuous monolithic carbon aerogel (CAG) throughout the matrix. This nanostructured matrix both provides a dramatic increase in active surface area of the electrodes, and has the potential to address mechanical issues associated with matrix-dominated failures. The effect of the initial reaction mixture composition is assessed for both the CAG modified carbon fibre electrodes and resulting devices. A low temperature CAG modification of carbon fibres was evaluated using poly(3,4-ethylenedioxythiophene) (PEDOT) to enhance the electrochemical performance. For the multifunctional structural electrolyte, simple crosslinked gels have been replaced with bicontinuous structural epoxy-ionic liquid hybrids that offer a much better balance between the conflicting demands of rigidity and molecular motion. The formation of both aerogel precursors and the multifunctional electrolyte are described, including the influence of key components, and the defining characteristics of the products. Working structural supercapacitor composite prototypes have been produced and characterised electrochemically. The effect of introducing the necessary multifunctional resin on the mechanical properties has also been assessed. Larger scale demonstrators have been produced including a full size car boot/trunk lid.
SUMMARY
Background
Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma ...(HCC) is not well described.
Aim
To determine the efficacy of oral anti‐viral agents in reducing HCC risk in relationship with other known factors.
Methods
Published studies of at least 20 CHB patients treated with an oral anti‐viral agent and followed for >2 years were analysed for incidence of HCC per 100 person years follow‐up.
Results
Pooled homogeneous data from six studies showed lamivudine (LAM) treatment (n = 3306) to reduce HCC risk by 51% compared with no treatment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence of 1.3 per 100 person years, independent of the agent used. Patient age >50 years and hepatitis B virus‐DNA detectability at HCC diagnosis increased risk of HCC by twofold with a 10‐fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta‐regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity.
Conclusions
Lamivudine treatment significantly reduces the incidence of HCC compared with no treatment. However, HCC still develops at a rate of 1.3 per 100 patient years in CHB patients receiving an oral anti‐viral agent. This finding highlights the need for continued HCC surveillance, particularly in CHB patients with inadequate viral suppression, older age and cirrhosis.
Background & Aims N -acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non–acetaminophen-related acute liver failure. Methods In a prospective, double-blind ...trial, acute liver failure patients without clinical or historical evidence of acetaminophen overdose were stratified by site and coma grade and assigned randomly to groups that were given NAC or placebo (dextrose) infusion for 72 hours. The primary outcome was overall survival at 3 weeks. Secondary outcomes included transplant-free survival and rate of transplantation. Results A total of 173 patients received NAC (n = 81) or placebo (n = 92). Overall survival at 3 weeks was 70% for patients given NAC and 66% for patients given placebo (1-sided P = .283). Transplant-free survival was significantly better for NAC patients (40%) than for those given placebo (27%; 1-sided P = .043). The benefits of transplant-free survival were confined to the 114 patients with coma grades I–II who received NAC (52% compared with 30% for placebo; 1-sided P = .010); transplant-free survival for the 59 patients with coma grades III–IV was 9% in those given NAC and 22% in those given placebo (1-sided P = .912). The transplantation rate was lower in the NAC group but was not significantly different between groups (32% vs 45%; P = .093). Intravenous NAC generally was well tolerated; only nausea and vomiting occurred significantly more frequently in the NAC group (14% vs 4%; P = .031). Conclusions Intravenous NAC improves transplant-free survival in patients with early stage non–acetaminophen-related acute liver failure. Patients with advanced coma grades do not benefit from NAC and typically require emergency liver transplantation.
Recurrent HCV infection following liver transplantation can lead to accelerated allograft injury that is difficult to treat with interferon. The aim of this study is to describe the first ever use of ...an interferon‐free, all oral regimen in a liver transplant recipient with severe recurrent HCV. A 54‐year‐old male with HCV genotype 1b developed severe cholestatic HCV at 6 months posttransplant with ascites, AST 503 IU/mL, alkaline phosphatase of 298 IU/mL, HCV RNA of 12 000 000 IU/mL, and histological cholestasis with pericellular fibrosis. Sofosbuvir, an HCV polymerase inhibitor (400 mg/day), and daclatasvir, an HCV NS5A replication complex inhibitor (60 mg/day), were co‐administered for 24 weeks. Within 4 weeks of initiating treatment, serum HCV RNA levels became undetectable and liver biochemistries normalized with concomitant resolution of ascites. The patient achieved a sustained virological response with undetectable HCV RNA at 9 months posttreatment. During and following treatment, the daily dose and blood level of tacrolimus remained stable and unchanged. The rapid and sustained suppression of HCV replication in this liver transplant recipient provides great promise for the use of combination oral antiviral regimens in other immunosuppressed and interferon refractory HCV patients.
A patient with severe cholestatic hepatitis C virus genotype 1b infection at nine months after liver transplantation was successfully treated with a six‐month course of oral sofosbuvir in combination with daclatasvir and remains HCV RNA negative during posttreatment follow‐up with improved liver biochemistries and health.
Quantum dots embedded within nanowires represent one of the most promising technologies for applications in quantum photonics. Whereas the top-down fabrication of such structures remains a ...technological challenge, their bottom-up fabrication through self-assembly is a potentially more powerful strategy. However, present approaches often yield quantum dots with large optical linewidths, making reproducibility of their physical properties difficult. We present a versatile quantum-dot-in-nanowire system that reproducibly self-assembles in core-shell GaAs/AlGaAs nanowires. The quantum dots form at the apex of a GaAs/AlGaAs interface, are highly stable, and can be positioned with nanometre precision relative to the nanowire centre. Unusually, their emission is blue-shifted relative to the lowest energy continuum states of the GaAs core. Large-scale electronic structure calculations show that the origin of the optical transitions lies in quantum confinement due to Al-rich barriers. By emitting in the red and self-assembling on silicon substrates, these quantum dots could therefore become building blocks for solid-state lighting devices and third-generation solar cells.
We present the results of a study which uses spectral energy distribution (SED) fitting to investigate the evolution of the equivalent width (EW) of the Hα emission line in star-forming galaxies over ...the redshift interval 1 < z < 5. After first demonstrating the ability of our SED-fitting technique to recover EW(Hα) using a sample of galaxies at z ≃ 1.3 with EW(Hα) measurements from 3D-HST grism spectroscopy, we proceed to apply our technique to samples of spectroscopically confirmed and photometric-redshift selected star-forming galaxies at z ≥ 1 in the CANDELS (Cosmic Assembly Near-IR Deep Extragalactic Legacy Survey) UDS and GOODS-S fields. Confining our analysis to a constant stellar mass range (9.5 < log (M
⋆/M⊙) < 10.5), we find that the median EW(Hα) evolves only modestly with redshift, reaching a rest-frame value of EW(Hα) =301 ± 30 Å by redshift z ≃ 4.5. Furthermore, using estimates of star formation rate (SFR) based on both UV luminosity and Hα line flux, we use our galaxy samples to compare the evolution of EW(Hα) and specific star formation rate (sSFR). Our results indicate that over the redshift range 1 < z < 5, the evolution displayed by EW(Hα) and sSFR is consistent, and can be adequately parametrized as ∝ (1 + z)1.0 ± 0.2. As a consequence, over this redshift range, we find that the sSFR and rest-frame EW(Hα) of star-forming galaxies with stellar masses M
⋆
${\simeq }\, 10^{10}{\,\rm M_{{\odot }}}$
are related by EW(Hα)/Å = (63 ± 7) × sSFR/Gyr−1. Given the current uncertainties in measuring the SFRs of high-redshift galaxies, we conclude that EW(Hα) provides a useful independent tracer of sSFR for star-forming galaxies out to redshifts of z = 5.
PDF
